reports
Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Sess...
Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2 MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies’ senior leadership who will share insight into the Company’s portfolio of genomics-based...
Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Pla...
Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification ...
Genetic Technologies Announces Global Launch of geneType™ on Wholly Ow...
Genetic Technologies Announces Global Launch of geneType™ on Wholly Owned EasyDNA platform CHARLOTTE, N.C., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch of the geneType™ Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries, setting the stage for the potential significant expansion of the Company’s current A$7.5m annual revenues....
Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Sess...
Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on August 15 MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on August 15, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature some of Genetic Technologies Senior Executives, who will share insight into the Company’s portfolio of genomic...
Genetic Technologies Strategic Restructure Driving USA Sales Growth
Genetic Technologies Strategic Restructure Driving USA Sales Growth CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales growth (particul...
Genetic Technologies Announces Appointment of Chief Financial Officer ...
Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years’ experience operating across life sciences, technology and consumer segments th...
GeneType to Enter Canadian and New Zealand Markets
GeneType to Enter Canadian and New Zealand Markets Genomics-based testing brand expands international presence as pilot influencer campaign fuels sales CHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, today announced the introduction of geneType’s suite of genetic risk assessment tests to Canada and New Zealand. Dovetailing geneType’s recent expansion to the US market under its partnership with hea...
GeneType Identifies 79.5% of People Tested are at Risk of Serious Dise...
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease Results from commercial sales of predictive testing across the US and Australia establish clear advantages of geneType Risk Assessment Tests for a more preventive approach in disease management CHARLOTTE, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide...
Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Ses...
Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27 CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insight into the Company’s portf...
Genetic Technologies Expands Operational Capacity in North America
Genetic Technologies Expands Operational Capacity in North America Global leader in personalized predictive genetics launches testing operations for geneType disease risk assessments at US based, world-leading genetic laboratory, Gene by Gene CHARLOTTE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, today announces the start of testing operations in the United States for its revolutionary geneType™ genetic risk assessment product series. Gen...
GeneType and Stayhealthy Announce Landmark Distribution Agreement for ...
GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are excited to announce a major distribution agreement. This partnership will bring GTG's innovative Multi-Risk Test to a broader audience in the online pharmacy channel across North America, empowering individuals to ...
GTG Launches Revolutionary geneType Test covering 100% Risk of Breast ...
GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer MELBOURNE, Australia, May 29, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30, assesses a woman’s risk of cancer due to hereditary, includin...
GeneType and Humanise Health host “Know Your Risk” Event
GeneType and Humanise Health host “Know Your Risk” Event PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the Know Your Risk event held yesterday at The Langham Pasadena has set a new standard for women’s health initiatives, highlighting the transformative potential of genetic testing and risk assessment. Organized by GeneType and Humanise Health, in partnership with Thermo Fisher Scientific and Creator...
GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 7...
GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees MELBOURNE, Australia, May 06, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the execution of a strategic joint sales & marketing agreement with US based Wellworks for You Inc. (Wellworks). As part of the agreement, Wellworks will incorporate the geneType portfolio of tests into its fully flexible, scalable employee well...
Appendix 4C & Quarterly Business Update – March 2024
Appendix 4C & Quarterly Business Update – March 2024 Launching our most comprehensive test and expanding into new global markets MELBOURNE, Australia, April 30, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 30 March 2024 (Q3 FY24). Key highlights: Cash Receipts totalling A$1.8m for the quarter ending March 2024.Launched targeted digital strategy for geneTyp...
Genetic Technologies Announces Closing of US$2 Million Registered Dire...
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at a...
Genetic Technologies Announces $2 Million Registered Direct Offering
Genetic Technologies Announces $2 Million Registered Direct Offering MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies"), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, a...
New Precision Oncology Tests to Drive Personalised Therapies and Impro...
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The proprietary-developed tests will provide invaluable information to medical oncologists, h...
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the company’s latest milestones along with our clinical adoption of the Company’s groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia. The geneType team has achieved clinical proof of concept in key markets including ge...
GTG to pilot GeneType in Breast Screen centers across the U.S.
GTG to pilot GeneType in Breast Screen centers across the U.S. MELBOURNE, Australia, April 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the company is establishing a clinical implementation study with breast imaging centers across New York, Miami and Houston. The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently somewhat fragmented. It will b...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.